Menu
Home
People
Places
Arts
History
Plants & Animals
Science
Life & Culture
Technology
Reference.org
Regdanvimab
open-in-new
<p>Regdanvimab, sold under the brand name Regkirona, is a <a href="/facts/Human_monoclonal_antibody/4rUBWB87">human monoclonal antibody</a> used for the treatment of <a href="/facts/COVID-19/YsUgvsaX">COVID-19</a>. The antibody is directed against the <a href="/facts/Coronavirus_spike_protein/JTcbvUn2">spike protein</a> of <a href="/facts/SARS-CoV-2/DxF8rDc1">SARS-CoV-2</a>. It is developed by <a href="/facts/Celltrion/SmlX8HSv">Celltrion</a>. The medicine is given by infusion (drip) into a vein. </p><p>The most common side effects include infusion-related reactions, including allergic reactions and anaphylaxis. </p><p>Regdanvimab was authorized for medical use in the European Union in November 2021. </p>